Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
Hajime Yasuda, Yutaka Tsukune, Naoki Watanabe, Kazuya Sugimoto, Ayana Uchimura, Misa Tateyama, Yosuke Miyashita, Yusuke Ochi, Norio Komatsu
Topics & Concepts
RituximabCoronavirus disease 2019 (COVID-19)MedicinePneumoniaFollicular lymphomaLymphomaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyAntibodyAntibody therapyImmunologyMaintenance therapy2019-20 coronavirus outbreakInternal medicineMonoclonal antibodyChemotherapyInfectious disease (medical specialty)OutbreakDiseaseLymphoma Diagnosis and TreatmentInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Lymphocytic Leukemia Research